Oh wow, got it. Thanks.
Posts tagged Value Pickr
VST Industries: Puff full of power? (25-07-2024)
Bonus of 1:10; however results seems bad
https://www.bseindia.com/xml-data/corpfiling/AttachLive//483f3cf3-16a5-47bf-8b24-14c19f2c2f05.pdf
Bulk Deals Bi-Weekly Log (25-07-2024)
Bulk Deals Daily Log
14th Bulk Deals Log
Date: 24/07/2024
NSE Link: https://www.nseindia.com/report-detail/display-bulk-and-block-deals
BSE Link: BSE Equity : Bulk Deals
Hi Guys, I missed the log for two days because I was running a temperature. Making up for it here.
- Aurum Proptech
This is a very interesting company. It is in a domain which is going to see rapid growth with the kind of growth real estate is seeing in India. There seems to be a turnaround in the works with the operations. Definitely one should dig deeper into this.
Investor who bought: Ghalla Bhansali Stock Brokers
Quantity: 1.54 Lakh
Price: 163.29
Quant Firm Interest
- Apex Frozen Foods
- Arihant Capital Markets
- Arrow Greentech
- Avanti Feeds
- Antony Waste Handling
- Borosil Renewables
- Coastal Corporation
Laurus Labs – Can Business Transform to Next Level? (25-07-2024)
Am I the only one who has a feeling that doctor sahab mamu bna rhe hai?
I was going through the press release and found very funny comments. Funny because they make no sense. They are put there just to show off (maybe).
“We are leveraging power of our comprehensive technology platform & commercial excellence to advance manufacturing of several clinical programs and maximising the value impact of our integrated model.” (it seems jitni bhi English samaj aai, sab ek line me likh di).
Doctor sahab has been quoted saying momentum in CDMO business. Yet CDMO business is down by good 14%.
And then under CDMO business highlight, tone changes to “Soft growth on expected lines….”
In investor presentation for CDMO business, they have mentioned “Soft growth on expected lines driven by significant resource allocation towards delivering multiple high value complex programs”. So they allocated resources to high value complex business and the CDMO segment de-grew. Isn’t that a paradox?
Now they are saying H2 will be good. Since FY23 (when they were targeting to do $1bn topline), their goal post has always moved ahead by 2 quarters.
“Pricing dynamics across ARV product basket stable but a bit subdued for broader API portfolio”. If this sentence makes any sense, please do explain me.
Under FDF, they have signed a new customer. But obviously, business will only come after multiple quarters. Everything is in the future.
Bio division is “Continued positive market demand” and yet it de-grew by 14%.
Multiple projects coming up only in FY27. Like the one mentioned above for FDF. Large scale commercial fermentation capacity at Vizag coming up in FY27.
As you scroll down the investor presentation, you will notice how “H2 FY25” will change to “Q4 FY25” and “by end of FY25”. So, now the H2 targeted (better) performance is moved to year end.
On the positive side, atleast they are not playing the game of “adjusted EBIDTA”
Sarcasm aside, my point is what management is saying is completely different from what business is saying. In current euphoric market, one needs to tread with caution. Personally, I don’t see margin of safety in the valuation, nor is the management commentary comforting.
DIsclosure: Hold 5% of portfolio in LL. Will exit tomorrow and move to other API company where management has actually walked the talk in Q1 FY25.
WPIL Ltd – Global Water Pumps (25-07-2024)
Other income from sale of nuclear assets got added to eps.
Manappuram Finance (25-07-2024)
Will not have impact
Discussion Thread ‘Smallcap Hunter’ is missing: Poof! Gone (25-07-2024)
this is Shiba Inu a crypto token on Ethereum Blockchain, absolutely useless in both crypto and real world. Yet it commands an astronomical market cap of 9B$
Its just a liquidity fueled mania, an extravagant display of greater fool theory in play. at least our small caps have are engaged in some meaningful business no matter how inflated their valuations are.
I am not good at timing the peaks, nor do I have the temperament to handle such volatility. Those who can, kudos to them. I continue to hold onto names that fit my rules and thesis and sell them at valuations that I’m not comfortable holding, I might sell them sooner and miss out on gains, make mistakes, learn. Indexes are just distractions, manage your risk and focus on individual businesses.
Smallcap momentum portfolio (25-07-2024)
@Mudit.Kushalvardhan you are not wrong. Any criteria we introduce like standard deviation or VCP or turnover value or EMA is used to manage entry of stocks in the pf. And that is done to fine tune the performance.
Pf returns are governed by price action only. Anything else we do to fine tune will result in tempering the return while reducing drawdown.
Therefore, the efficacy of any criteria is evaluated by looking at returns and drawdowns.